The new year arrived with a ton of momentum for those in the Cystic Fibrosis Foundation community, as the FDA approved the use of "Trikafta" in October 2019. Trikafta is a triple combination therapy that will ultimately treat about 90% of the CF population and generally had very positive results during its clinical trial stage.
The goal of therapies like Trikafta are to relieve symptoms and potentially IMPROVE quality of life, as those with CF continue to fight day in and day out for the opportunity to lead self-fulfilling lives.
Though therapy combinations may not have the same effects on each individualized case, the approval of breakthrough treatments give everyone within the CF community HOPE. Hope that hard work leads to individual health improvements. Hope that family members and friends see their loved one's quality of life improve. Hope for those with CF who cannot take this specific drug, because they know we are getting closer to the next advancement. Hope for all people that are, or have been, affected by cystic fibrosis, as we grasp the significance of being one step closer to a cure.
Essential research and development of new therapies such as Trikafta are possible because of YOUR SUPPORT. Great Strides teams, such as JohnnyP's Crew, are proof that incredible things can happen when we work together. Please help us continue to fight in any way you can.
Foundation-Sponsored Indoor and Outdoor Events and Gatherings
The Foundation is closely following the evolving coronavirus outbreak. We will continue to monitor coronavirus guidance from the Centers for Disease Control and Prevention and assess whether we need to change any scheduled events.
To reduce the risk of getting and spreading germs at CF Foundation-sponsored events, we ask that everyone follow basic best practices by regularly cleaning your hands with soap and water or with an alcohol-based hand gel, covering your cough or sneeze with a tissue or your inner elbow, and maintaining a safe 6-foot distance from anyone with a cold or infection. Medical evidence shows that germs may spread among people with CF through direct and indirect contact, as well as through droplets that travel short distances when a person coughs or sneezes. These germs can lead to worsening symptoms and speed decline in lung function.
To further help reduce the risk of cross-infection, the Foundation's attendance policy recommends inviting only one person with CF to attend the indoor portion of a Foundation-sponsored event at a specific time. For the outdoor portion, the Foundation recommends that all people with CF maintain a safe 6-foot distance from each other at all times.